The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union
Abstract
CONTEXT: Biologicals are a relatively new class of medicines that carry specific risks (eg, immunogenicity). However, limited information is available on the nature and timing of safety problems with their use that were identified after approval. OBJECTIVE: To determine the nature, frequency, and timing of safety-related regulatory actions for biologicals following approval in the United States and/or the European Union. DESIGN AND SETTING: Follow-up of a group of biologicals approved in the United States and/or European Union between January 1995 and June 2007. Vaccines, allergenic products, and products for further manufacture and transfusion purposes were excluded. MAIN OUTCOME MEASURES: Nature, frequency, and timing of safety-related regulatory actions defined as (1) dear healthcare professional letters (United States) and direct healthcare professional communications (European Union), (2) black box warnings (United States), and (3) safety-related marketing withdrawals (United States and European Union) issued between January 1995 and June 2008. RESULTS: A total of 174 biologicals were approved (136 in the United States and 105 in the European Union, of which 67 were approved in both regions). Eighty-two safety-related regulatory actions (46 dear healthcare professional letters, 17 direct healthcare professional communications, 19 black box warnings, and no withdrawals) were issued for 41 of the 174 different biologicals (23.6%). The probability of a first safety-related regulatory action, derived from Kaplan-Meier analyses, was 14% (95% confidence interval [CI], 9%-19%) 3 years after approval and 29% (95% CI, 20%-37%) 10 years after approval. Biologicals first in class to obtain approval had a higher risk for a first safety-related regulatory action compared with later approved products in that class (12.0/1000 vs 2.9/1000 months, respectively; hazard ratio, 3.7 [95% CI, 1.5-9.5]). Warnings mostly concerned the classes general disorders and administration site conditions, infections and infestations, immune system disorders and neoplasms benign, malignant, and unspecified. CONCLUSIONS: The nature of safety problems identified after approval for biologicals is often related to the immunomodulatory effect (infections). Because the biologicals first to be approved in a class were more likely to be subjected to regulatory action, close monitoring is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 2×
“The observed cytokine storm following infusion had not been observed in the preclinical studies of TGN1412.(16) To obtain valuable results from the preclinical (toxicology) studies, a relevant test animal should not only be selected based on pharmacological activity and low immunogenicity, but suitable pharmacokinetic…”
BackgroundTiming of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Biopharmaceutical benchmarks 2006
Walsh, G. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-769 · Cited by 359
Winthrop, K. L. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0336 · Cited by 280
Shankar, G., Pendley, C., & Stein, K. E. (2007) · Nature Biotechnology · doi:10.1038/nbt1303 · Cited by 260
Detection, verification, and quantification of adverse drug reactions
Stricker, B. H., & Psaty, B. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.44 · Cited by 221
Immunogenicity of biopharmaceuticals
Kessler, M., Goldsmith, D., & Schellekens, H. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl476 · Cited by 209
Bakke, O. M., Manocchia, M., de Abajo, F., Kaitin, K. I., & Lasagna, L. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90078-0 · Cited by 208
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs
Crommelin, D. J. A., Storm, G., Verrijk, R., de Leede, L., Jiskoot, W., & Hennink, W. E. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00376-4 · Cited by 197
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Astashkina, A., Mann, B., & Grainger, D. W. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.001 · Cited by 424
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Immunogenicity of protein aggregates—Concerns and realities
Wang, W., Singh, S. K., Li, N., Toler, M. R., King, K. R., & Nema, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.040 · Cited by 266
Pharmaceutical research and development: what do we get for all that money?
Light, D. W., & Lexchin, J. R. (2012) · BMJ · doi:10.1136/bmj.e4348 · Cited by 258
Metadata
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-10-22
- Volume
- 300
- Issue
- 16
- Pages
- 1887
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2157584018
- Cited by
- 261
- References
- 25
- FWCI
- 36.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. https://app.cochat.ai/papers/10.1001/jama.300.16.1887
- The paper
- Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. (2008). JAMA. https://doi.org/10.1001/jama.300.16.1887
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.